Beatrice Casadei

IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola

*This is an algorithmically generated author record based on publicly available information.

See Latest Publications

See Most Cited Publications

SciProfiles

ORCID Profile

Google Scholar

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Research Subjects

Lymphomas

Research Interests

Beatrice Casadei has a total of 498 co-authors. Here are the top co-authors by number of shared publications:

Pier Luigi Zinzani
IRCCS Azienda Ospedaliero‐Universitaria di Bologna. Istituto di Ematologia “Seràgnoli”, Azienda Ospedaliero‐Universitaria di Bologna ‐ IRCCS Bologna Italy
75 shared publications
Annalisa Chiappella
Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
31 shared publications
Francesca Bonifazi
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
31 shared publications
Lisa Argnani
Dipartimento di Scienze Mediche e Chirurgiche (DIMEC) Alma Mater Studiorum Università of Bologna Bologna Italy
30 shared publications
Ilaria Cutini
Struttura Organizzativa Dipartimentale Ematologia, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
29 shared publications
Mauro Krampera
Hematology and Bone Marrow Transplant Unit, Section of Biomedicine of Innovation, Department of Engineering for Innovative Medicine, University of Verona, 37134 Verona, Italy
29 shared publications

Latest Publications

Sort by

Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
by Federico Stella, Annalisa Chiappella, Beatrice Casadei, Stefania Bramanti, Silva Ljevar, Patrizia Chiusolo, Alice Di Rocco, Maria C. Tisi, Matteo G. Carrabba, Ilaria Cutini, et al.
Supplementary Figure 2 – Overall survival tisa-cel vs axi-cel in bridging failure
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure 2 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
by Federico Stella, Annalisa Chiappella, Beatrice Casadei, Stefania Bramanti, Silva Ljevar, Patrizia Chiusolo, Alice Di Rocco, Maria C. Tisi, Matteo G. Carrabba, Ilaria Cutini, et al.
Supplementary Figure 2 – Overall survival tisa-cel vs axi-cel in bridging failure
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
by Federico Stella, Annalisa Chiappella, Beatrice Casadei, Stefania Bramanti, Silva Ljevar, Patrizia Chiusolo, Alice Di Rocco, Maria C. Tisi, Matteo G. Carrabba, Ilaria Cutini, et al.
Supplementary Table 5 – List of centers and patients enrolled
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table 5 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
by Federico Stella, Annalisa Chiappella, Beatrice Casadei, Stefania Bramanti, Silva Ljevar, Patrizia Chiusolo, Alice Di Rocco, Maria C. Tisi, Matteo G. Carrabba, Ilaria Cutini, et al.
Supplementary Table 5 – List of centers and patients enrolled
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
by Federico Stella, Annalisa Chiappella, Beatrice Casadei, Stefania Bramanti, Silva Ljevar, Patrizia Chiusolo, Alice Di Rocco, Maria C. Tisi, Matteo G. Carrabba, Ilaria Cutini, et al.
Supplementary Table 3 – Summary of real-world data
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table 3 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
by Federico Stella, Annalisa Chiappella, Beatrice Casadei, Stefania Bramanti, Silva Ljevar, Patrizia Chiusolo, Alice Di Rocco, Maria C. Tisi, Matteo G. Carrabba, Ilaria Cutini, et al.
Supplementary Table 3 – Summary of real-world data
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
by Federico Stella, Annalisa Chiappella, Beatrice Casadei, Stefania Bramanti, Silva Ljevar, Patrizia Chiusolo, Alice Di Rocco, Maria C. Tisi, Matteo G. Carrabba, Ilaria Cutini, et al.
Supplementary Table 1 – Baseline variables associated with ORR at day 90, CRR at day 90, PFS, and OS
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table 1 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
by Federico Stella, Annalisa Chiappella, Beatrice Casadei, Stefania Bramanti, Silva Ljevar, Patrizia Chiusolo, Alice Di Rocco, Maria C. Tisi, Matteo G. Carrabba, Ilaria Cutini, et al.
Supplementary Table 1 – Baseline variables associated with ORR at day 90, CRR at day 90, PFS, and OS
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
by Federico Stella, Annalisa Chiappella, Beatrice Casadei, Stefania Bramanti, Silva Ljevar, Patrizia Chiusolo, Alice Di Rocco, Maria C. Tisi, Matteo G. Carrabba, Ilaria Cutini, et al.
Supplementary Table 2 – Bivariable Cox model CAR-HEMATOTOX in tisa-cel and axi-cel
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table 2 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
by Federico Stella, Annalisa Chiappella, Beatrice Casadei, Stefania Bramanti, Silva Ljevar, Patrizia Chiusolo, Alice Di Rocco, Maria C. Tisi, Matteo G. Carrabba, Ilaria Cutini, et al.
Supplementary Table 2 – Bivariable Cox model CAR-HEMATOTOX in tisa-cel and axi-cel
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
by Federico Stella, Annalisa Chiappella, Beatrice Casadei, Stefania Bramanti, Silva Ljevar, Patrizia Chiusolo, Alice Di Rocco, Maria C. Tisi, Matteo G. Carrabba, Ilaria Cutini, et al.
Supplementary Table 4 – Detailed eligibility criteria in accordance with AIFA (Agenzia Italiana Farmaco)
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table 4 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
by Federico Stella, Annalisa Chiappella, Beatrice Casadei, Stefania Bramanti, Silva Ljevar, Patrizia Chiusolo, Alice Di Rocco, Maria C. Tisi, Matteo G. Carrabba, Ilaria Cutini, et al.
Supplementary Table 4 – Detailed eligibility criteria in accordance with AIFA (Agenzia Italiana Farmaco)
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
by Federico Stella, Annalisa Chiappella, Beatrice Casadei, Stefania Bramanti, Silva Ljevar, Patrizia Chiusolo, Alice Di Rocco, Maria C. Tisi, Matteo G. Carrabba, Ilaria Cutini, et al.
Supplementary figure 3 – Outcomes according to bridging therapy
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure 3 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
by Federico Stella, Annalisa Chiappella, Beatrice Casadei, Stefania Bramanti, Silva Ljevar, Patrizia Chiusolo, Alice Di Rocco, Maria C. Tisi, Matteo G. Carrabba, Ilaria Cutini, et al.
Supplementary figure 3 – Outcomes according to bridging therapy
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
by Federico Stella, Annalisa Chiappella, Beatrice Casadei, Stefania Bramanti, Silva Ljevar, Patrizia Chiusolo, Alice Di Rocco, Maria C. Tisi, Matteo G. Carrabba, Ilaria Cutini, et al.
Supplementary Figure 1 – Survival in entire population
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure 1 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
by Federico Stella, Annalisa Chiappella, Beatrice Casadei, Stefania Bramanti, Silva Ljevar, Patrizia Chiusolo, Alice Di Rocco, Maria C. Tisi, Matteo G. Carrabba, Ilaria Cutini, et al.
Supplementary Figure 1 – Survival in entire population
Open Access
Website
Google Scholar
Cited by 3
- 15 June 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
The Prognostic Role of Interim [18F]FDG PET/CT in Diffuse Large B-Cell Lymphoma: An Updated Systematic Review and Meta-analysis
by Domenico Albano, Stephane Chauvie, Alessio Rizzo, Francesco Bertagna, Beatrice Casadei, Umberto Vitolo, Alessandra Tucci, Pier Luigi Zinzani, Luca Guerra
Website
Google Scholar
- 15 June 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
Open Access
The Prognostic Role of Interim [18F]FDG PET/CT in Diffuse Large B-Cell Lymphoma: An Updated Systematic Review and Meta-analysis
by Domenico Albano, Stephane Chauvie, Alessio Rizzo, Francesco Bertagna, Beatrice Casadei, Umberto Vitolo, Alessandra Tucci, Pier Luigi Zinzani, Luca Guerra
Cited by 3
Website
Google Scholar
Cited by 2
- 14 June 2026
- Published by Elsevier in European Journal of Cancer
Outcomes of CAR T‐Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study
by Nicole Fabbri, Beatrice Casadei, Annalisa Chiappella, Federico Stella, Livia Donzelli, Eugenio Galli, Marcello Riva, Massimo Martino, Anna Maria Barbui, Maurizio Musso, et al.
Website
Google Scholar
- 14 June 2026
- Published by Elsevier in European Journal of Cancer
Outcomes of CAR T‐Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study
by Nicole Fabbri, Beatrice Casadei, Annalisa Chiappella, Federico Stella, Livia Donzelli, Eugenio Galli, Marcello Riva, Massimo Martino, Anna Maria Barbui, Maurizio Musso, et al.
Cited by 2

Show all